Stefan Sillau
Concepts (461)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 25 | 2026 | 613 | 2.440 |
Why?
| | Epilepsies, Partial | 7 | 2026 | 63 | 1.380 |
Why?
| | Seizures | 12 | 2026 | 491 | 1.080 |
Why?
| | Alzheimer Disease | 6 | 2025 | 639 | 1.080 |
Why?
| | Multiple Sclerosis | 9 | 2025 | 491 | 1.040 |
Why?
| | Palliative Care | 14 | 2026 | 1032 | 0.950 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2025 | 161 | 0.890 |
Why?
| | Drug Resistant Epilepsy | 5 | 2026 | 144 | 0.830 |
Why?
| | Quality of Life | 18 | 2026 | 3246 | 0.750 |
Why?
| | Epilepsy | 5 | 2024 | 399 | 0.610 |
Why?
| | Caregivers | 9 | 2024 | 1091 | 0.550 |
Why?
| | Middle Aged | 58 | 2026 | 36821 | 0.530 |
Why?
| | Aged | 46 | 2026 | 26514 | 0.500 |
Why?
| | Humans | 116 | 2026 | 147293 | 0.480 |
Why?
| | Neurons | 1 | 2025 | 1672 | 0.480 |
Why?
| | Cognition | 8 | 2025 | 1286 | 0.470 |
Why?
| | Natalizumab | 4 | 2021 | 41 | 0.470 |
Why?
| | Stroke | 5 | 2026 | 1287 | 0.460 |
Why?
| | Male | 74 | 2026 | 73950 | 0.450 |
Why?
| | Aging | 2 | 2025 | 1992 | 0.450 |
Why?
| | Parkinsonian Disorders | 3 | 2020 | 43 | 0.440 |
Why?
| | Healthcare Disparities | 4 | 2026 | 740 | 0.430 |
Why?
| | Female | 74 | 2026 | 80076 | 0.430 |
Why?
| | Fingolimod Hydrochloride | 3 | 2020 | 40 | 0.430 |
Why?
| | Aged, 80 and over | 21 | 2026 | 8430 | 0.430 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 479 | 0.400 |
Why?
| | Anticonvulsants | 3 | 2026 | 253 | 0.400 |
Why?
| | Retrospective Studies | 36 | 2026 | 17560 | 0.390 |
Why?
| | Young Adult | 26 | 2026 | 14437 | 0.390 |
Why?
| | Adult | 44 | 2026 | 41405 | 0.390 |
Why?
| | Immunologic Factors | 3 | 2020 | 261 | 0.370 |
Why?
| | Psychotherapy, Group | 2 | 2026 | 79 | 0.370 |
Why?
| | Atherosclerosis | 4 | 2019 | 411 | 0.350 |
Why?
| | Cognition Disorders | 3 | 2024 | 551 | 0.340 |
Why?
| | Charcot-Marie-Tooth Disease | 2 | 2022 | 22 | 0.330 |
Why?
| | Cannabidiol | 2 | 2024 | 142 | 0.330 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 100 | 0.330 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1145 | 0.320 |
Why?
| | Chagas Disease | 2 | 2021 | 42 | 0.320 |
Why?
| | Ambulatory Care | 3 | 2020 | 625 | 0.320 |
Why?
| | Music Therapy | 2 | 2021 | 24 | 0.310 |
Why?
| | Sinusitis | 3 | 2021 | 230 | 0.310 |
Why?
| | Rural Health Services | 2 | 2025 | 139 | 0.290 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 0.290 |
Why?
| | Torticollis | 2 | 2019 | 21 | 0.290 |
Why?
| | Meningitis, Cryptococcal | 2 | 2019 | 34 | 0.280 |
Why?
| | Rituximab | 2 | 2020 | 211 | 0.280 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 83 | 0.280 |
Why?
| | Emergency Medical Services | 2 | 2026 | 691 | 0.280 |
Why?
| | Dystonic Disorders | 2 | 2019 | 27 | 0.280 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 83 | 0.270 |
Why?
| | Adolescent | 21 | 2026 | 22825 | 0.260 |
Why?
| | Cardiomyopathies | 2 | 2021 | 339 | 0.250 |
Why?
| | Medical Staff, Hospital | 2 | 2021 | 80 | 0.250 |
Why?
| | Spirituality | 4 | 2021 | 88 | 0.250 |
Why?
| | Myelitis | 2 | 2018 | 107 | 0.240 |
Why?
| | Treatment Outcome | 17 | 2026 | 11947 | 0.240 |
Why?
| | Neurological Rehabilitation | 1 | 2026 | 16 | 0.240 |
Why?
| | Chlorophenols | 1 | 2026 | 12 | 0.240 |
Why?
| | Dissociative Disorders | 1 | 2026 | 30 | 0.240 |
Why?
| | Cannabis | 2 | 2024 | 518 | 0.240 |
Why?
| | Colorado | 14 | 2025 | 4591 | 0.230 |
Why?
| | Tetrazoles | 1 | 2026 | 50 | 0.230 |
Why?
| | Carbamates | 1 | 2026 | 51 | 0.230 |
Why?
| | Suburban Health Services | 1 | 2025 | 4 | 0.230 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 70 | 0.220 |
Why?
| | Sepsis | 2 | 2022 | 671 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 125 | 0.220 |
Why?
| | Urban Health Services | 1 | 2025 | 69 | 0.220 |
Why?
| | Neurosurgical Procedures | 2 | 2017 | 207 | 0.220 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.220 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 14 | 0.220 |
Why?
| | Candidemia | 1 | 2024 | 16 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 3980 | 0.210 |
Why?
| | Arterial Occlusive Diseases | 1 | 2025 | 90 | 0.210 |
Why?
| | Prevalence | 9 | 2024 | 2889 | 0.210 |
Why?
| | Thrombectomy | 1 | 2025 | 79 | 0.210 |
Why?
| | Candida | 1 | 2024 | 46 | 0.210 |
Why?
| | Ischemic Attack, Transient | 1 | 2025 | 71 | 0.210 |
Why?
| | Vulnerable Populations | 1 | 2026 | 177 | 0.210 |
Why?
| | Brain | 6 | 2023 | 3009 | 0.210 |
Why?
| | Nasal Polyps | 2 | 2016 | 59 | 0.210 |
Why?
| | Aquaporin 4 | 1 | 2024 | 102 | 0.200 |
Why?
| | Cell Death | 1 | 2025 | 383 | 0.200 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 11 | 0.200 |
Why?
| | Community Health Services | 1 | 2026 | 231 | 0.200 |
Why?
| | Adaptation, Psychological | 5 | 2020 | 736 | 0.200 |
Why?
| | Dronabinol | 2 | 2024 | 251 | 0.200 |
Why?
| | Child Abuse | 2 | 2022 | 558 | 0.200 |
Why?
| | Brain Ischemia | 2 | 2025 | 362 | 0.200 |
Why?
| | Dimethyl Fumarate | 2 | 2020 | 12 | 0.200 |
Why?
| | Patient Reported Outcome Measures | 2 | 2026 | 506 | 0.200 |
Why?
| | Telemedicine | 2 | 2024 | 978 | 0.190 |
Why?
| | Cost of Illness | 3 | 2021 | 327 | 0.190 |
Why?
| | Child | 16 | 2025 | 22979 | 0.190 |
Why?
| | Risk Assessment | 7 | 2026 | 3784 | 0.190 |
Why?
| | Self Report | 4 | 2025 | 887 | 0.190 |
Why?
| | Fatigue | 1 | 2025 | 367 | 0.190 |
Why?
| | Inpatients | 3 | 2021 | 556 | 0.190 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 141 | 0.190 |
Why?
| | Patient Discharge | 3 | 2026 | 1002 | 0.190 |
Why?
| | Cohort Studies | 10 | 2026 | 6099 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2026 | 324 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 337 | 0.180 |
Why?
| | Patient Care Team | 3 | 2019 | 712 | 0.180 |
Why?
| | Severity of Illness Index | 8 | 2020 | 2973 | 0.180 |
Why?
| | Migraine Disorders | 1 | 2024 | 115 | 0.180 |
Why?
| | Conversion Disorder | 1 | 2022 | 10 | 0.180 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1121 | 0.180 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 47 | 0.180 |
Why?
| | Vagus Nerve Stimulation | 1 | 2022 | 28 | 0.180 |
Why?
| | Frontotemporal Dementia | 1 | 2022 | 56 | 0.170 |
Why?
| | Memory Consolidation | 1 | 2021 | 14 | 0.170 |
Why?
| | Biomarkers | 4 | 2025 | 4351 | 0.170 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 27 | 0.170 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.170 |
Why?
| | Exercise Therapy | 1 | 2026 | 489 | 0.170 |
Why?
| | Atrophy | 4 | 2024 | 201 | 0.170 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 5 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 784 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 895 | 0.160 |
Why?
| | Risk Factors | 12 | 2026 | 11017 | 0.160 |
Why?
| | Guideline Adherence | 1 | 2025 | 590 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1224 | 0.160 |
Why?
| | Basal Ganglia Diseases | 1 | 2020 | 9 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 183 | 0.160 |
Why?
| | Vitamin D | 2 | 2015 | 405 | 0.160 |
Why?
| | Sleep | 3 | 2021 | 895 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2025 | 395 | 0.160 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 28 | 0.160 |
Why?
| | Incidence | 6 | 2024 | 2954 | 0.150 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.150 |
Why?
| | Cytokines | 3 | 2022 | 2086 | 0.150 |
Why?
| | Disease Progression | 4 | 2022 | 2890 | 0.150 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 6011 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2023 | 786 | 0.150 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2022 | 115 | 0.150 |
Why?
| | Time Factors | 8 | 2026 | 7173 | 0.150 |
Why?
| | Neurovascular Coupling | 1 | 2019 | 10 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 284 | 0.150 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 1220 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 41 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 222 | 0.140 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.140 |
Why?
| | Critical Care Outcomes | 1 | 2018 | 11 | 0.140 |
Why?
| | Shock, Septic | 1 | 2021 | 230 | 0.140 |
Why?
| | Electronic Health Records | 2 | 2021 | 1214 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2627 | 0.140 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.140 |
Why?
| | Restless Legs Syndrome | 1 | 2018 | 20 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 39 | 0.140 |
Why?
| | Streptococcal Infections | 1 | 2021 | 178 | 0.140 |
Why?
| | Cannabinoids | 1 | 2020 | 184 | 0.140 |
Why?
| | Depression | 3 | 2026 | 1599 | 0.140 |
Why?
| | Fluoxetine | 1 | 2018 | 57 | 0.140 |
Why?
| | Psychometrics | 2 | 2019 | 739 | 0.140 |
Why?
| | Proxy | 1 | 2018 | 37 | 0.130 |
Why?
| | Aftercare | 1 | 2020 | 225 | 0.130 |
Why?
| | Basal Ganglia | 1 | 2018 | 60 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 97 | 0.130 |
Why?
| | United States | 11 | 2026 | 16313 | 0.130 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 78 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4604 | 0.130 |
Why?
| | Nutrition Surveys | 1 | 2019 | 279 | 0.130 |
Why?
| | Electroencephalography | 4 | 2022 | 570 | 0.130 |
Why?
| | Neurology | 1 | 2019 | 117 | 0.130 |
Why?
| | Subthalamic Nucleus | 1 | 2018 | 85 | 0.130 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2017 | 67 | 0.130 |
Why?
| | Child, Preschool | 5 | 2025 | 12016 | 0.130 |
Why?
| | Down Syndrome | 2 | 2022 | 526 | 0.130 |
Why?
| | Cranial Nerve Diseases | 1 | 2017 | 44 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 840 | 0.130 |
Why?
| | Apoptosis | 1 | 2025 | 2454 | 0.120 |
Why?
| | Rats | 1 | 2025 | 5613 | 0.120 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2017 | 50 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 269 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2019 | 276 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2021 | 901 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2018 | 122 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 109 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 425 | 0.120 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 8 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 145 | 0.120 |
Why?
| | Orbital Diseases | 1 | 2016 | 37 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 563 | 0.120 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5476 | 0.120 |
Why?
| | Cerebellum | 1 | 2018 | 227 | 0.120 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
| | Meningioma | 1 | 2016 | 88 | 0.110 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 96 | 0.110 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 143 | 0.110 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 180 | 0.110 |
Why?
| | Regression Analysis | 2 | 2018 | 1003 | 0.110 |
Why?
| | Family | 2 | 2024 | 690 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.110 |
Why?
| | Deep Brain Stimulation | 1 | 2018 | 222 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 2017 | 0.110 |
Why?
| | Motor Activity | 1 | 2019 | 719 | 0.110 |
Why?
| | Dementia | 1 | 2019 | 332 | 0.110 |
Why?
| | Data Collection | 2 | 2022 | 652 | 0.110 |
Why?
| | Craniofacial Abnormalities | 1 | 2015 | 78 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2022 | 3027 | 0.100 |
Why?
| | Hemodynamics | 1 | 2019 | 1127 | 0.100 |
Why?
| | Rhinitis | 1 | 2016 | 169 | 0.100 |
Why?
| | Ureteroscopy | 1 | 2014 | 15 | 0.100 |
Why?
| | Patient Readmission | 1 | 2020 | 777 | 0.100 |
Why?
| | Depressive Disorder | 1 | 2017 | 379 | 0.100 |
Why?
| | Physicians | 1 | 2023 | 961 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 490 | 0.100 |
Why?
| | Urolithiasis | 1 | 2014 | 11 | 0.100 |
Why?
| | Neonatal Screening | 1 | 2016 | 185 | 0.100 |
Why?
| | Vitamin D Deficiency | 2 | 2015 | 190 | 0.100 |
Why?
| | Aspirin | 2 | 2016 | 406 | 0.100 |
Why?
| | Behavioral Medicine | 1 | 2014 | 39 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2017 | 376 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2019 | 552 | 0.100 |
Why?
| | Extremities | 1 | 2014 | 144 | 0.100 |
Why?
| | Eosinophilia | 1 | 2016 | 224 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 568 | 0.100 |
Why?
| | Retinopathy of Prematurity | 1 | 2016 | 183 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2024 | 1344 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2016 | 288 | 0.100 |
Why?
| | Chronic Disease | 2 | 2016 | 1844 | 0.100 |
Why?
| | Internet | 2 | 2024 | 696 | 0.100 |
Why?
| | Airway Obstruction | 1 | 2015 | 153 | 0.100 |
Why?
| | Feasibility Studies | 3 | 2026 | 1147 | 0.100 |
Why?
| | Demography | 1 | 2014 | 283 | 0.100 |
Why?
| | Pulmonary Ventilation | 1 | 2013 | 82 | 0.100 |
Why?
| | Tonsillectomy | 1 | 2015 | 106 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2024 | 2080 | 0.090 |
Why?
| | Length of Stay | 2 | 2025 | 1371 | 0.090 |
Why?
| | Primary Prevention | 1 | 2015 | 228 | 0.090 |
Why?
| | Birth Weight | 1 | 2016 | 522 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1166 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 776 | 0.090 |
Why?
| | Refugees | 1 | 2014 | 84 | 0.090 |
Why?
| | Calcinosis | 1 | 2014 | 234 | 0.090 |
Why?
| | Coronary Vessels | 1 | 2014 | 246 | 0.090 |
Why?
| | Movement | 1 | 2014 | 293 | 0.090 |
Why?
| | Mental Disorders | 1 | 2021 | 1188 | 0.090 |
Why?
| | Prognosis | 4 | 2023 | 4383 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2791 | 0.090 |
Why?
| | Teaching Rounds | 1 | 2013 | 74 | 0.090 |
Why?
| | Weight Gain | 1 | 2016 | 566 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 382 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 2017 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1082 | 0.090 |
Why?
| | Prospective Studies | 6 | 2025 | 8164 | 0.080 |
Why?
| | Anxiety | 3 | 2026 | 1149 | 0.080 |
Why?
| | Environmental Monitoring | 1 | 2013 | 347 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 448 | 0.080 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 303 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 303 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 403 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2022 | 3448 | 0.080 |
Why?
| | Tissue Donors | 1 | 2014 | 427 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 280 | 0.080 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 130 | 0.080 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 251 | 0.080 |
Why?
| | Age of Onset | 2 | 2023 | 568 | 0.080 |
Why?
| | Tissue and Organ Procurement | 1 | 2014 | 350 | 0.080 |
Why?
| | Surveys and Questionnaires | 6 | 2019 | 6164 | 0.070 |
Why?
| | Polysomnography | 3 | 2015 | 240 | 0.070 |
Why?
| | Cross Infection | 1 | 2012 | 261 | 0.070 |
Why?
| | Obesity | 2 | 2021 | 3149 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2023 | 3660 | 0.070 |
Why?
| | Models, Statistical | 1 | 2013 | 677 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3216 | 0.070 |
Why?
| | Health Status | 1 | 2014 | 839 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 754 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2013 | 697 | 0.070 |
Why?
| | Calcium | 1 | 2014 | 1197 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2136 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1279 | 0.070 |
Why?
| | Asthma | 3 | 2016 | 1805 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1338 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1785 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 3022 | 0.060 |
Why?
| | Pilot Projects | 2 | 2026 | 1912 | 0.060 |
Why?
| | Urban Population | 2 | 2025 | 502 | 0.060 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 616 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1798 | 0.060 |
Why?
| | Patient Participation | 2 | 2022 | 449 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 787 | 0.060 |
Why?
| | Recurrence | 2 | 2020 | 1151 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1280 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2012 | 928 | 0.060 |
Why?
| | Animals | 2 | 2025 | 38410 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1386 | 0.060 |
Why?
| | Influenza, Human | 1 | 2011 | 634 | 0.060 |
Why?
| | Critical Illness | 1 | 2012 | 907 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.050 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 941 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1431 | 0.050 |
Why?
| | Neurologists | 1 | 2024 | 23 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1157 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 56 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1672 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 25 | 0.050 |
Why?
| | American Heart Association | 1 | 2025 | 363 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1776 | 0.050 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 315 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1720 | 0.050 |
Why?
| | Primary Health Care | 1 | 2014 | 1759 | 0.050 |
Why?
| | Death | 1 | 2024 | 132 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 98 | 0.050 |
Why?
| | Postural Balance | 1 | 2026 | 254 | 0.050 |
Why?
| | Vaccination | 1 | 2011 | 1443 | 0.050 |
Why?
| | Myelin P0 Protein | 1 | 2022 | 7 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 125 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1598 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2025 | 258 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 11 | 0.050 |
Why?
| | tau Proteins | 1 | 2023 | 108 | 0.050 |
Why?
| | Home Care Services | 1 | 2026 | 293 | 0.050 |
Why?
| | Organ Size | 1 | 2023 | 465 | 0.050 |
Why?
| | Pain | 2 | 2018 | 794 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 975 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1977 | 0.040 |
Why?
| | Facial Expression | 1 | 2022 | 75 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 430 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 219 | 0.040 |
Why?
| | Polymerization | 1 | 2022 | 127 | 0.040 |
Why?
| | Vagus Nerve | 1 | 2022 | 92 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 177 | 0.040 |
Why?
| | Catalysis | 1 | 2022 | 305 | 0.040 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.040 |
Why?
| | Oncology Service, Hospital | 1 | 2021 | 15 | 0.040 |
Why?
| | Interneurons | 1 | 2022 | 125 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2133 | 0.040 |
Why?
| | Immune System | 1 | 2022 | 181 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 176 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2920 | 0.040 |
Why?
| | Serine | 1 | 2021 | 143 | 0.040 |
Why?
| | Outpatients | 1 | 2024 | 450 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4141 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 684 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 438 | 0.040 |
Why?
| | Medical Informatics | 1 | 2021 | 100 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 178 | 0.040 |
Why?
| | Astrocytes | 1 | 2022 | 230 | 0.040 |
Why?
| | Electrodes, Implanted | 1 | 2020 | 114 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 141 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 290 | 0.040 |
Why?
| | Multiple System Atrophy | 1 | 2019 | 8 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 406 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 390 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2023 | 698 | 0.040 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2019 | 18 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2022 | 284 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 687 | 0.040 |
Why?
| | Income | 1 | 2020 | 208 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Lewy Body Disease | 1 | 2019 | 33 | 0.040 |
Why?
| | Music | 1 | 2019 | 48 | 0.040 |
Why?
| | Infant | 3 | 2018 | 10194 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2019 | 137 | 0.030 |
Why?
| | Logistic Models | 2 | 2014 | 2142 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 88 | 0.030 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 134 | 0.030 |
Why?
| | Phosphorus | 1 | 2018 | 90 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.030 |
Why?
| | Gait | 1 | 2021 | 317 | 0.030 |
Why?
| | Stroke Volume | 1 | 2021 | 658 | 0.030 |
Why?
| | Carnitine | 1 | 2018 | 91 | 0.030 |
Why?
| | Muscle Spasticity | 1 | 2018 | 63 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 546 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 874 | 0.030 |
Why?
| | Health Services | 1 | 2019 | 113 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 878 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 83 | 0.030 |
Why?
| | Gadolinium | 1 | 2018 | 84 | 0.030 |
Why?
| | Neural Pathways | 1 | 2019 | 320 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 170 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 360 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 575 | 0.030 |
Why?
| | Registries | 1 | 2026 | 2434 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2019 | 312 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 583 | 0.030 |
Why?
| | Exophthalmos | 1 | 2016 | 18 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 1005 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 8 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 626 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Brain Mapping | 1 | 2019 | 550 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 19 | 0.030 |
Why?
| | Neuroimaging | 1 | 2019 | 309 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 19 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 799 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 989 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 789 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 48 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 158 | 0.030 |
Why?
| | Qualitative Research | 1 | 2024 | 1735 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 313 | 0.030 |
Why?
| | Self Efficacy | 1 | 2019 | 422 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 144 | 0.030 |
Why?
| | Hospitalization | 1 | 2026 | 2496 | 0.030 |
Why?
| | Sleep Stages | 1 | 2015 | 77 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 537 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2018 | 449 | 0.030 |
Why?
| | Contrast Media | 1 | 2018 | 500 | 0.030 |
Why?
| | Electromyography | 1 | 2017 | 419 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 932 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 93 | 0.030 |
Why?
| | Thinness | 1 | 2015 | 100 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 148 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 3372 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2015 | 82 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 98 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 60 | 0.030 |
Why?
| | Sampling Studies | 1 | 2014 | 98 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1093 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2014 | 124 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1281 | 0.020 |
Why?
| | Sternotomy | 1 | 2013 | 25 | 0.020 |
Why?
| | Leukotriene E4 | 1 | 2013 | 24 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 117 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2013 | 18 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2016 | 6543 | 0.020 |
Why?
| | Lithotripsy | 1 | 2014 | 49 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1084 | 0.020 |
Why?
| | Thoracotomy | 1 | 2013 | 88 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2013 | 148 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 852 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2013 | 122 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 145 | 0.020 |
Why?
| | Spirometry | 1 | 2013 | 235 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 267 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 74 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2013 | 81 | 0.020 |
Why?
| | Vital Capacity | 1 | 2013 | 293 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 329 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2013 | 451 | 0.020 |
Why?
| | Gestational Age | 1 | 2016 | 997 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.020 |
Why?
| | Paper | 1 | 2011 | 9 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 779 | 0.020 |
Why?
| | Personnel, Hospital | 1 | 2011 | 30 | 0.020 |
Why?
| | Critical Care | 1 | 2017 | 705 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4130 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2013 | 227 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 319 | 0.020 |
Why?
| | Premature Birth | 1 | 2015 | 390 | 0.020 |
Why?
| | Exercise Test | 1 | 2013 | 636 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 329 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2013 | 721 | 0.020 |
Why?
| | Patient Admission | 1 | 2012 | 220 | 0.020 |
Why?
| | Cause of Death | 1 | 2012 | 475 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1342 | 0.020 |
Why?
| | Recovery of Function | 1 | 2013 | 724 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 1018 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1772 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1868 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2011 | 541 | 0.020 |
Why?
| | Mice | 1 | 2022 | 18491 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|